全球血浆蛋白治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计血浆蛋白疗法市场将从 2025 年的 238.5 亿美元成长到 2034 年的 430.1 亿美元，2026 年至 2034 年的复合年增长率为 6.77%。

由于血浆衍生产品在免疫力缺乏、出血性疾病和神经系统疾病的治疗中应用日益广泛，全球血浆蛋白治疗市场正在扩张。人们对罕见疾病的认识不断提高以及诊断能力的不断增强，也推动了市场需求。已开发市场和新兴市场医疗保健支出的成长进一步促进了市场发展。

主要驱动因素包括慢性病和罕见病患疾病的上升、血浆分馏技术的进步以及对免疫球蛋白的强劲需求。血浆采集网路的扩展和监管核准的推进，使得供给能力不断提高。然而，对捐献血浆的依赖以及严格的监管要求可能会限制其快速扩张。

随着研究不断开发新的治疗应用，前景依然强劲。全球血浆捐献活动的增加和处理技术的进步将有助于维持供应稳定。随着医疗系统优先考虑特化生物疗法，市场预计将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球血浆蛋白治疗市场：依产品分类

• 市场分析、洞察与预测
• 白蛋白
• 免疫球蛋白
• 血浆衍生因子VIII
• 其他的

第五章 全球血浆蛋白治疗市场：依应用划分

• 市场分析、洞察与预测
• 血友病
• 原发性免疫力缺乏（PIDD）
• 特发性血小板减少紫斑症（ITP）
• 其他的

第六章 全球血浆蛋白治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第七章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第八章：公司简介

• 主要公司的市占率分析
• 公司简介
  • CSL
  • Grifols SA
  • Takeda
  • Octapharma AG
  • Biotest AG
  • Kedrion SPA
  • China Biologic Products Holdings Inc
  • Sanquin
  • LFB SA
  • ADMA Biologics Inc
  • Bioverativ

The Plasma Protein Therapeutic Market size is expected to reach USD 43.01 Billion in 2034 from USD 23.85 Billion (2025) growing at a CAGR of 6.77% during 2026-2034.

The global plasma protein therapeutic market is expanding due to increasing use of plasma-derived products for treating immune deficiencies, bleeding disorders, and neurological conditions. Rising awareness of rare diseases and expanding diagnostic capabilities are boosting demand. Growing healthcare expenditure in developed and emerging economies further supports market growth.

Major drivers include increasing prevalence of chronic and rare diseases, advancements in plasma fractionation technologies, and strong demand for immunoglobulins. Expanding plasma collection networks and regulatory approvals enhance supply capacity. However, reliance on donor plasma and stringent regulatory requirements may limit rapid expansion.

Future prospects remain strong as research advances new therapeutic applications. Increasing global plasma donation initiatives and technological improvements in processing will support supply stability. The market is expected to grow steadily as healthcare systems prioritize specialized biologic therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Albumin
• Immunoglobulin
• Plasma-derived Factor VIII
• Others

By Application

• Hemophilia
• Primary Immunodeficiency Disorder (PIDD)
• Idiopathic Thrombocytopenic Purpura (ITP)
• Others

COMPANIES PROFILED

• CSL, Grifols SA, Takeda, Octapharma AG, Biotest AG, Kedrion SpA, China Biologic Products Holdings Inc, Sanquin, LFB SA, ADMA Biologics Inc, Bioverativ
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Albumin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunoglobulin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Plasma-derived Factor VIII Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Hemophilia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Primary Immunodeficiency Disorder (PIDD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Idiopathic Thrombocytopenic Purpura (ITP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA PROTEIN THERAPEUTIC MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Product
  • 6.2.2 By Application
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Product
  • 6.3.2 By Application
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Product
  • 6.4.2 By Application
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Product
  • 6.5.2 By Application
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Product
  • 6.6.2 By Application
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PLASMA PROTEIN THERAPEUTIC INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 CSL
  • 8.2.2 Grifols S.A
  • 8.2.3 Takeda
  • 8.2.4 Octapharma AG
  • 8.2.5 Biotest AG
  • 8.2.6 Kedrion S.P.A
  • 8.2.7 China Biologic Products Holdings Inc
  • 8.2.8 Sanquin
  • 8.2.9 LFB S.A
  • 8.2.10 ADMA Biologics Inc
  • 8.2.11 Bioverativ